Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cardiocomm Solutions (V.EKG) extends loan agreement and adds to BoD

Stockhouse Editorial
0 Comments| December 16, 2015

{{labelSign}}  Favorites
{{errorMessage}}

Cardiocomm Solutions (TSX: V.EKG, Forum) gained a reprieve when the company announced today that it had negotiated an extension to the date of payment of a line credit it secured from MD Primer Inc.

According to the news release, the company now has until March 31, 2016 to repay. The terms of the original $1.0 million line or credit loan agreement announced January 18, 2013, will remain intact during the extension period except the amount available to Cardiocomm will be $900,000.

The company will use this period to work to retire the LOC through acquisition of funding through alternative funding sources and from sales-based revenue.

In other news, the company announced that Robert Caines, Managing Partner at Paley Advisors, had been appointed to Cardiocomm’s board of directors. Mr. Caines, an veteran mergers and acquisitions executive, has 30 years of experience in business start-up, and growth and management.

Mr. Caines addition will assist with Cardiocomm’s 2016 plan to increase HeartCheck™ ECG PEN sales and to introduce new Bluetooth medical and consumer ECG devices globally.

Cardiocomm Solutions was in the news recently when the North York, Ontario-based company announced at the end of November that its HeartCheck™ and SMART monitoring ECG technologies were used in Colorado State University’s coordinated canine atrial fibrillation clinical trial.

Shares were down 12.50% to $0.035 per share.

Currently there are 114.7m outstanding shares with a market cap of $4.0 million.

FULL DISCLOSURE: Cardiocomm Solutions is a Stockhouse Publishing client.


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company